<?xml version="1.0" encoding="UTF-8"?>
<p id="p0115">Overall, across 6 WHO regions, 155 samples were from general populations, 137 were from hepatology clinics, and 84 were from selected population groups (
 <xref rid="fig2" ref-type="fig">Fig. 2</xref>, 
 <xref rid="appsec1" ref-type="sec">supplementary appendix 10</xref>). We excluded from general population estimates 19 studies that sampled isolated island or remote indigenous communities (
 <xref rid="appsec1" ref-type="sec">supplementary appendix 11</xref>). Repeated longitudinal testing of the same population was reported from 12 samples. Overall, 120,293 HBsAg-positive individuals were tested for anti-HDV using various assays (
 <xref rid="appsec1" ref-type="sec">supplementary appendix 12</xref>); in 12.7% of the studies, the anti-HDV testing method was not specified. Overall, 5,065 anti-HDV positive participants were tested for HDV RNA (
 <xref rid="fig3" ref-type="fig">Fig. 3</xref>).
</p>
